Antibody Information
General Information of This Antibody
| Antibody ID | ANI0RKEWW |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Anti-Matriptase mAb M69 |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa |
|||||
| Antigen Name | Suppressor of tumorigenicity 14 protein (ST14) |
Antigen Info | ||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
M69-MMAE [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 82.10% (Day 18) | Positive ST14 expression (ST14+++/++) | ||
| Method Description |
Five thousand cells per well were plated in RPMI 1,640 media supplemented with 10% FBS. After overnight culture, media was removed and fresh media containing the ADC was added and incubated for different time periods.
|
||||
| In Vitro Model | Mantle cell lymphoma | JeKo-1 cells | CVCL_1865 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
5.29 ug/mL±0.28 ug/mL
|
Positive ST14 expression (ST14+++/++) | ||
| Method Description |
Five thousand cells per well were plated in RPMI 1,640 media supplemented with 10% FBS. After overnight culture, media was removed and fresh media containing the ADC was added and incubated for different time periods.
|
||||
| In Vitro Model | Mantle cell lymphoma | Mino cells | CVCL_1872 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
7.20 ug/mL±2.01 ug/mL
|
Positive ST14 expression (ST14+++/++) | ||
| Method Description |
Five thousand cells per well were plated in RPMI 1,640 media supplemented with 10% FBS. After overnight culture, media was removed and fresh media containing the ADC was added and incubated for different time periods.
|
||||
| In Vitro Model | Mantle cell lymphoma | MAVER-1 cells | CVCL_1831 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
7.69 ug/mL±0.29 ug/mL
|
Positive ST14 expression (ST14+++/++) | ||
| Method Description |
Five thousand cells per well were plated in RPMI 1,640 media supplemented with 10% FBS. After overnight culture, media was removed and fresh media containing the ADC was added and incubated for different time periods.
|
||||
| In Vitro Model | Mantle cell lymphoma | Z-138 cells | CVCL_B077 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
13.78 ug/mL±2.15 ug/mL
|
Positive ST14 expression (ST14+++/++) | ||
| Method Description |
Five thousand cells per well were plated in RPMI 1,640 media supplemented with 10% FBS. After overnight culture, media was removed and fresh media containing the ADC was added and incubated for different time periods.
|
||||
| In Vitro Model | Mantle cell lymphoma | JeKo-1 cells | CVCL_1865 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.